GENERAL COMMENTS
In this study, Bungard and colleagues compared the type of anticoagulant treatment for venous thromboembolism among patients discharged from hospitals in Edmonton, Regina and rural Alberta.
I have a few questions and comments:
• What was the hypothesis of the investigators? The authors should formulate a hypothesis in the introduction.
• What is the message the authors want to convey?
• Table 2 shows that DOACs were most commonly used in rural Alberta (50% versus 28% and 23% respectively). As the authors indicate, the use of DOACs in rural areas is advantageous because it obviates the need for laboratory tests. It seems plausible that this was the most important reason for DOACs to be used more frequently in rural areas. Did the authors test this hypothesis?
• How many patients experienced recurrent thromboembolism among those discharged with DOACs as compared to those discharged with traditional anticoagulant therapy?
• How many patients experienced complications among those discharged with DOACs as compared to those discharged with traditional anticoagulant therapy?
• The authors should not refer to manuscripts under review (reference 14 and 15) with all of the chart reviews, which is a major advantage in the study. In addition, it is of major advantage that the authors had access to clinical variables.
Major comments 1) Methods section: Consider to rearrange the methods section as follows: Data sources, study setting, participants, "outcomes" or variables, statistical analysis. I think it is important to describe the data source in the beginning, because it allows the reader to understand where the data comes from, and this is important for the understanding of the rest of the methods section.
2) Limitation: The largest limitation in this study is the years investigated. It is very likely that treatment patterns have changed in Canada since 2015.
3) I understand why it is interesting to investigate the differences between rural and urban/academic areas, but it is unclear to the reader why Edmonton and Regina is investigated separately. should you not just divide the population according to rural and urban/academic areas? I think it is very difficult for readers outside of Canada to understand the context. Otherwise it should be stated clearly why it is of interest to look at these three different areas.
Minor comments 1) Abstract: I think the objective should be restated, because the result and conclusion section does not answer the objective as it is stated in the abstract.
2) Methods: please write somewhere that the study was conducted in Canada.
3) Methods: Please add what "other indications" for anticoagulation therapy refers to. 4) Methods: How did you determine exposure to anticoagulant therapy? 5) Methods: What happens to a patient that was discharged from the emergency department that was later admitted to hospital? what this person included in both this manuscript and the other manuscript that dealt with emergency department visits? 4) Methods: How did you determine exposure to anticoagulant therapy, 6) Strengths and limitations: the first sentence "we present herein the largest cohort of patient…" is simply not true. Similar studies can be mentioned, which also includes outcomes and that also describe a similar patient population [1] [2] [3] [4] [5] [6] . Please rephrase this.
References: 
Overall, I feel these three manuscripts provide useful data on characteristics and management of patients between ED discharge and hospital discharge, but need major reworking, consolidation into one paper, and pruning of the questions asked. I suggest rejection with the option for resubmission of a reworked paper.
Description of study:
This is a retrospective review including patients with a diagnosis of acute VTE discharged from inpatient wards or emergency departments from several academic and community hospitals in Alberta and Saskatchewan, Canada. The findings are reported separately for patients discharged from hospital and those discharged from ED, and a third manuscript compares characteristics and management of patients between the two settings. In all three, the primary aim is to compare the proportion of patients receiving parenteral anticoagulation +/-VKA (traditional) vs. DOAC. Traditional therapy vs. DOAC is also compared based on DVT vs. PE, lower vs. higher clot burden, rural vs. urban/academic centres. Follow-up plan was also compared for the urban vs. rural settings.
Introduction:
Overall, I feel the justification for the study objectives is not well elaborated in the introduction. In a retrospective design where risk of bias is high, it is important to choose the few critical questions of interest to reduce Type I error. The authors fail to justify why the descriptions and comparisons made would be of interest to the wider community, outside of Alberta and Saskatchewan. Prospective registries will provide higher quality data for some of the questions. The PREFER in VTE registry was not referenced in this paper, but provides relevant data from one year earlier. The GARFIELD-VTE registry will also provide more data in a much larger and geographically diverse patient population, and initial results have been presented. These need to be referenced and results compared. A Spanish study (Jimenez et al. Medicine (Baltimore). 2017;96(48):e8796.) reviewed 800 patients who were evaluated in ED, many of whom went on to hospital admission.
However, none of these studies provide detailed analysis by inpatient vs. outpatient management, which is the focus of the current study. Therefore, I believe the questions of greatest interest involve comparing management between hospitalized patients and those discharged from ED. I don't think the results should be separately presented for patients discharged from hospital and ED. I think the separate papers examining hospital and ED should be combined with an expanded paper comparing ED vs. hospitalized patients.
A major limitation is the retrospective nature of the study, and lack of data on therapy after discharge. Therefore, the data tells us about practice patterns in the hospital and ED, but not about how patients are treated overall. Patients could be discharged on parenteral therapy from ED, with the expectation that they would be seen in clinic and possibly switched to DOAC.
Specific recommendations:
The patient population admitted vs. discharged from ED could be compared re: baseline characteristics (age, sex, renal function, etc.); DVT vs. PE; iliac vs. femoral to popliteal vs. distal DVT; and the proportion of PE patients with low sPESI who were admitted and high sPESI who were discharged could be noted. The follow-up plans can also be described.
Overall data on DOAC vs. parenteral/VKA should be presented, then compared between DVT vs. PE and hospital vs. ED discharge. Secondarily, the proportion can be compared between urban vs. rural; academic vs. community hospital. It can also be compared by severity/extent of thrombosis. Data on cancer diagnosis between DOAC and traditional therapy also needs to be described better, because the data are from the pre-HOKUSAI Cancer VTE/Select-D era.
The proportion of patients for whom each reported variable was evaluable needs to be reported.
Many of the other comparisons made are of lesser interest, and distract from the main focus: correlation between renal function and DOAC use is fairly predictable and doesn't need to be reported unless there was an unexpected or alarming finding. The comparison between DOAC and traditional therapy for length of stay is also less informative, given the retrospective design and inability to draw conclusions about causation. Dosing of DOACs is an interesting question, but I am concerned about the validity of the data. Did the authors take into account therapy beginning at presentation in ED and throughout hospitalization? A patient who receives 5 days of LMWH, then 2 days of high-dose apixaban is less concerning than one who gets 2 days of high-dose apixaban only. I have a few questions and comments:
VERSION 1 -AUTHOR RESPONSE
We have altered our introduction to lead into a hypothesis (as opposed to a purpose).
Overall, our message is that there is modest uptake of DOACs in both urban centres (more with rural Alberta) given the early timing of this audit in relation to the Health Canada approval of the DOACs.
We did not test this hypothesis, as our study was retrospective in nature and did not allow us to contact patients. In collaboration with colleagues working in rural areas, however, this is noted to be an important factor in determining course of therapy.
While this is an important question, it is beyond the scope of what our study allowed us to identify. Given the design of our study and subsequent ethical approvals, we were not able to contact patients prospectively (as a waiver of consent was granted on the basis of the sheer volume of patients and that the investigators had no relationship with the patients) nor were we able to follow these patients once they left the hospital (we were limited to the documentation in the institution-based chart).
We have acknowledged this as a limitation both in the "Strengths and Limitations of this Study" (last bullet point) that follows the abstract as well as in the corresponding section prior to the Conclusion.
Please refer to our response above.
• The authors should not refer to manuscripts under review (reference 14 and 15)
We have left this in as per the direction of the editor. This study investigated the management of patients with acute venous thromboembolism discharged from hospital. The study is well written, and very thoroughly describes, the management of VTE patients. Clearly a tremendous amount of work has been put into it with all of the chart reviews, which is a major advantage in the study. In addition, it is of major advantage that the authors had access to clinical variables.
Major comments 1)
Methods section: Consider to rearrange the methods section as follows: Data sources, study setting, participants, "outcomes" or variables, statistical analysis. I think it is important to describe the data source in the beginning, because it allows the reader to understand where the data comes from, and this is important for the understanding of the rest of the methods section.
Done 2)
Limitation: The largest limitation in this study is the years investigated. It is very likely that treatment patterns have changed in Canada since 2015.
We agree with this and have referred to this data as a benchmark, and indicate (in the Strengths and Limitations section of the main paper) that the timing of the audit is reflective of early uptake of the DOACs. To further highlight this point, we have added the following (underlined) in the main paper under Strengths and Limitations:
The timing ofour audit is reflective of the early uptake of DOACs for the acute treatment of VTE given only rivaroxaban had Health Canada approval throughout the entire time interval audited and that prescribing patterns may have changed beyond the timing of the audit (March 2015).
3)
I understand why it is interesting to investigate the differences between rural and urban/academic areas, but it is unclear to the reader why Edmonton and Regina is investigated separately. should you not just divide the population according to rural and urban/academic areas? I think it is very difficult for readers outside of Canada to understand the context. Otherwise it should be stated clearly why it is of interest to look at these three different areas.
We separated out the 2 urban cities as we wanted to examine if there were regional differences in the use of DOACs given these cities are located in separate, yet adjacent provinces in Canada with different health authorities overseeing care delivery -as such, different physician practices may have occurred. While we anticipated early uptake of DOACs to be similar in both urban cities, we were not certain that this would occur. We have integrated more information throughout the manuscript to better describe why we have left the 2 urban centres separate to compare with the rural sites.
Minor comments 1)
Abstract: I think the objective should be restated, because the result and conclusion section does not answer the objective as it is stated in the abstract.
We have not changed our objective within the abstract -the objective as we understand should capture our overall purpose with our study outcomes -we do believe as stated it does this as follows: a) "To determine anticoagulant therapy at hospital discharge" (for our outcome measure we states comparing the proportion prescribed either traditional therapy or a DOAC) b)
"To describe factors affecting choice of therapy" (for our outcomes we state management based on setting, therapy choice based on DVT versus PE, clot burden and renal function was compared) 2) Methods: please write somewhere that the study was conducted in Canada. Done -both under study setting in the methods and the abstract.
3)
Methods: Please add what "other indications" for anticoagulation therapy refers to.
Done -we have provided examples in this sentence.
4)
Methods: How did you determine exposure to anticoagulant therapy?
Exposure to anticoagulant therapy was determined based on documentation in the institution-based medical records. We do believe this is now more clear in the manuscript based on the re-organization of our methods section and changes to be more explicit with our data collection.
5)
Methods: What happens to a patient that was discharged from the emergency department that was later admitted to hospital? what this person included in both this manuscript and the other manuscript that dealt with emergency department visits?
Patients presenting to the emergency department that went onto be admitted from the emergency department would only have been included in the hospitalized cohort of patients. If a patient presented to the emergency department, went home and then presented at a later time with an acute VTE, they would have been eligible for inclusion in our study. However, they only would have been included only if they met all inclusion criteria, including not being prescribed an anticoagulant at the point of presentation.
6)
Strengths and limitations: the first sentence "we present herein the largest cohort of patient…" is simply not true. Similar studies can be mentioned, which also includes outcomes and that also describe a similar patient population [1] [2] [3] [4] [5] [6] . Please rephrase this.
This has been re-phrased. Unfortunately, we did not collect other concomitant diagnoses (such as infections or psychiatric diagnoses) that may have contributed to a more prolonged length of stay in hospital. We focused our chart review on elements pertinent to VTE, collecting information specific to history of cancer, pulmonary disease, surgery, etc. We have altered our comparison with literature (in our discussion) that did identify factors that may also impact length of stay, as follows:
"While we did not set out to discern other factors that may have impacted length of hospital stay, our data is consistent with these, 19,22,23 as patients receiving a DOAC had a shorter median length of stay (Table 3) ." --RESULTS: appropriate dosing -consider mention of therapeutically significant drug-drug interactions that are labeled contraindications for use of DOACs (i.e. for the anti-Xa's, systemic treatment with strong inhibitors of both CYP 3A4 and P-gp) While this is a very interesting point, we do not believe this has implications with dosing of the DOACs (specifically for rivaroxaban and apixaban) that were used in our audit time interval. The drug-drug interactionslisted in the respective product monographs for apixaban and rivaroxaban either contraindicate certain combinations (e.g., ketoconazole or ritonavir with rivaroxaban or apixaban) or offer no empiric dosage adjustment for rivaroxaban or apixaban, but suggest use should be done with caution (e.g., clarithromycin). It is notable, however, that the edoxaban product monograph does suggest empiric dosage adjustments when certain agents are used in combination with edoxaban. This only applies to edoxaban, and edoxaban was not approved for use in Canada for the acute treatment of VTE during the time of our audit (and we did not see it used).
Thank you for this thorough review of anticoag prescribing practices. It will be interesting to see future data reflecting a time period when all DOACs (or at least Eliquis and Xarelto) have been approved and guideline-recommended Please leave your comments for the authors below Overall, I feel these three manuscripts provide useful data on characteristics and management of patients between ED discharge and hospital discharge, but need major reworking, consolidation into one paper, and pruning of the questions asked. I suggest rejection with the option for resubmission of a reworked paper.
Description of study: This is a retrospective review including patients with a diagnosis of acute VTE discharged from inpatient wards or emergency departments from several academic and community hospitals in Alberta and Saskatchewan, Canada. The findings are reported separately for patients discharged from hospital and those discharged from ED, and a third manuscript compares characteristics and management of patients between the two settings. In all three, the primary aim is to compare the proportion of patients receiving parenteral anticoagulation +/-VKA (traditional) vs. DOAC. Traditional therapy vs. DOAC is also compared based on DVT vs. PE, lower vs. higher clot burden, rural vs. urban/academic centres. Follow-up plan was also compared for the urban vs. rural settings.
Introduction:
Overall, I feel the justification for the study objectives is not well elaborated in the introduction. In a retrospective design where risk of bias is high, it is important to choose the few critical questions of interest to reduce Type I error. The authors fail to justify why the descriptions and comparisons made would be of interest to the wider community, outside of Alberta and Saskatchewan. Prospective registries will provide higher quality data for some of the questions. The PREFER in VTE registry was not referenced in this paper, but provides relevant data from one year earlier. The GARFIELD-VTE registry will also provide more data in a much larger and geographically diverse patient population, and initial results have been presented. These need to be referenced and results compared. A Spanish study (Jimenez et al. Medicine (Baltimore). 2017;96(48):e8796.) reviewed 800 patients who were evaluated in ED, many of whom went on to hospital admission. However, none of these studies provide detailed analysis by inpatient vs. outpatient management, which is the focus of the current study. Therefore, I believe the questions of greatest interest involve comparing management between hospitalized patients and those discharged from ED. I don't think the results should be separately presented for patients discharged from hospital and ED. I think the separate papers examining hospital and ED should be combined with an expanded paper comparing ED vs. hospitalized patients.
A major limitation is the retrospective natureof the study, and lack of data on therapy after discharge. Therefore, the data tells us about practice patterns in the hospital and ED, but not about how patients are treated overall. Patients could be discharged on parenteral therapy from ED, with the expectation that they would be seen in clinic and possibly switched to DOAC.
Specific recommendations:
We have done this in another paper, specifically targeting a comparison of those directly discharged from the ED vs those hospitalized.
As above for the comparison between those discharged from the ED vs hospital. Specific to those with cancer -the HOKUSAI Cancer / Select D data were published following our audit year, lending them less relevant to the time interval we assessed.
We did identify the proportion wherein we were missing data -please refer to Table 1 for demographics (report of proportions having weight and serum creatinine) and Table 2 for those not having documentation of anticoagulant prescribed.
Many of the other comparisons made are of lesser interest, and distract from the main focus: correlation between renal function and DOAC use is fairly predictable and doesn't need to be reported unless there was an unexpected or alarming finding. The comparison between DOAC and traditional therapy for length of stay is also less informative, given the retrospective design and inability to draw conclusions about causation. Dosing of DOACs is an interesting question, but I am concerned about the validity of thedata. Did the authors take into account therapy beginning at presentation in ED and throughout hospitalization? A patient who receives 5 days of LMWH, then 2 days of high-dose apixaban is less concerning than one who gets 2 days of high-dose apixaban only.
We have left the comparison for use of agent(s) in accordance with renal function. We acknowledge that we did not collect other factors that may have impacted length of stay and have integrated such into the discussion section of the manuscript. Specific to dosing, we did take into account the therapy(ies) provided in hospital to fairly quantify the up front dosing for rivaroxaban (3 weeks) and apixaban ( 1 week) so if a patient was prescribed LMWH this would have been counted in the up-front dosing portion.
VERSION 2 -REVIEW

REVIEWER
Caroline Sindet-Pedersen Herlev and Gentofte Hospital, Department of Cardiology REVIEW RETURNED 01-Aug-2018
GENERAL COMMENTS
The authors have answered my comments, and I have no further to add.
REVIEWER
Vinai Bhagirath McMaster University Canada REVIEW RETURNED
31-Jul-2018
GENERAL COMMENTS
This is a retrospective review of patients diagnosed with acute VTE who were discharged from hospital wards from rural and urban centres in Alberta and Saskatchewan, Canada. The stated primary outcome of interest was the proportion of patients prescribed parenteral anticoagulant +/-warfarin vs. DOAC. Several secondary outcomes are assessed -therapy choice based on setting, DVT vs. PE, VTE severity, and renal function; also, whether or not DOAC dosing was in accordance with the product label, differences in hospital stay based on therapy, and planned follow-up in the community.
The authors declined to combine the several manuscripts -I will leave it to the editors to decide how to handle this. The authors state that they would prefer to maintain separate papers as the purpose is to investigate regional differences in practice. This, of course, could still be done with a combined paper.
Response to previous review:
Thank you for your responses.
I still feel that data on use of DOACs in cancer in the era of the retrospective review would be valuable, especially as one of the purposes of this review is to act as a baseline to compare against future cross-sectional studies. It would be interesting to see whether use of DOACs in cancer was prevalent before HOKUSAI-Ca-VTE and SELECT-D, and whether it increased after publication of these studies.
Additional Points:
Introduction: Given the current introduction, one would hypothesize that DOACs would be used more commonly in rural sites (given lack of need for monitoring), and that DOAC use would be more prevalent in those with less severe thrombosis (as stated). If the hypothesis is that uptake would be modest in both settings due to the novelty of the agents, and this is indeed what is found, then the finding is of relatively limited interest. It is unfortunate that only 41 patients from rural Alberta were included, as one of the main hypotheses deals with the difference between urban and rural sites. If comparing rural and urban sites was a major consideration, the study should have been designed differently to increase the number of patients from the rural setting; however, some questions can certainly be answered even with 41 patients.
One important consideration that is not addressed is cost of DOACs, and the impact this may have on prescription patterns. The authors should state whether the cost of DOACs was universally covered by insurance schemes for the patients studied.
Methods: Page 7 line 5/6: the word "record" is likely missing after "hospitalbased"
Page 8 line 34/35: probably best to simply state that "we plan to separately publish 2 other analyses" rather than referring to manuscripts under review (as they may not be under review when this is published).
Results:
One point that becomes apparent is that few patients from rural Alberta are included, especially as subgroups are analysed (11 patients with DVT). This should be explicitly acknowledged as a limitation.
In Table 2 , P-values are given, but the details of the comparison should be made explicit in a Table footer (i.e. which values are actually being compared, given that each cell has 8 rows). A general rule is that the reader should be able to interpret a Table without having to refer back to the text for crucial information. In the text, P-values should be given for any comparison made. E.g page 9 line 30, and line 46-50. The reason is that, although it is self-evident that 60.8% is higher than 30%, the reader should have some indication of the likelihood that this reflects the population proportion without having to refer to the Table. Statements comparing values should not be made in the absence of a statistical test.
Page 9 line 37 -should clarify that "above knee" includes trifurcation, as otherwise "distal" clots would not have been detected at all in Edmonton.
Page 10 line 6-8 -There were only 36 patients with DVT who got a DOAC. I would suggest simply saying that there were too few patients to compare statistically. As you can see, the proportion of patients who had distal DVT who got a DOAC was nearly double that for patients with proximal DVT, which is clinically relevant if true, but P was only 0.14.
Page 10 line 17 -it would be important to know more details on the duration of higher dose rivaroxaban. Could be broken down as <7 days, 7-14 days, 14-21 days, or similar. There's a big difference clinically between giving 20 days of higher dose and giving only 7.
Page 10 line 21 -Data on weight is available, so I would also suggest assessing whether LMWH therapy was prescribed according to labeling. Can be compared to DOACs, and it would be interesting to note if there were differences in the supposedly familiar therapy which is more complicated vs. the newer therapy which is simpler.
Page 10 line 35-37 -why was the Chi-squared test not applied to this comparison (f/u with family doctor vs. specialist clinic) as was done for other comparisons?
Discussion
Page 12 line 26 -should mention in the discussion that the association between longer length of stay and traditional therapy in this study could be confounded by the fact that those with more severe thrombosis were more likely to receive traditional therapy and also would be expected to have longer length of stay.
Page 12 line 41 -I think the very small number of patients from rural Alberta needs to be mentioned as a limitation, especially as one of the main purposes of the study is to compare treatment patterns between urban and rural settings.
Page 13 line 48 -again, the P-value should be given for the comparison.
VERSION 2 -AUTHOR RESPONSE
Reviewer: 4 Reviewer Name: Vinai Bhagirath Institution and Country: McMaster University, Canada
Please leave your comments for the authors below This is a retrospective review of patients diagnosed with acute VTE who were discharged from hospital wards from rural and urban centres in Alberta and Saskatchewan, Canada. The stated primary outcome of interest was the proportion of patients prescribed parenteral anticoagulant +/-warfarin vs. DOAC. Several secondary outcomes are assessed -therapy choice based on setting, DVT vs. PE, VTE severity, and renal function; also, whether or not DOAC dosing was in accordance with the product label, differences in hospital stay based on therapy, and planned follow-up in the community.
While we agree that this is an interesting question, we also believe that many unique groups could be teased out of this data and that these objectives are beyond the scope of the stated objectives of this paper. Thesedata reflect practice patterns in 2014/15 when not all DOACs had approval for the acute treatment of VTE (apixaban came through in Nov 2014; edoxaban November 2016) so any reflections amongst this cohort of patients specific to cancer associated thrombosis would be very preliminary, and certainly pre-date data related to cancer associated thrombosis management with the DOACs. As well, there may have been differing policy related restrictions for anticoagulant use in patients with cancer between the geographic centres that deal with reimbursement (beyond the DOACs, some geographic areas cover LMWH in an ambulatory setting while others do not) which may have affected practices. Moreover, the way we have captured/reported "cancer" in the baseline demographic table is to encompass both those with active as well as a history of cancer, based on documentation in the medical records.
Our retrospective chart review was designed to assess practice patterns. We do not believe that the alignment of our stated hypothesis and results diminishes the interest of the results reported herein.
Provincial remuneration began for DVT for rivaroxaban in Sept 2013 (for Alberta) and July 2013 (for Saskatchewan). As the PE indication for rivaroxaban followed the DVT indication, provincial coverage also followed this pattern in both Alberta (June 2015) and Saskatchwean (June 2014). Apixaban did not have coverage until October 2015 for the acute treatment of VTE, and both dabigatran and edoxaban still do not have provincial remuneration in place.
We have added this information in the "Strengths and Limitations" section of the main paper.
Methods: Page 7 line 5/6: the word "record" is likely missing after "hospital-based"
Thank-you for finding this, you are absolutely correct. Added.
Given that the intent (in all likelihood) is for the 3 papers to be published in the same issue, I have left this as -I will defer to BMJ Open and alter accordingly.
Results:
We do agree that we had a small sample size from rural Alberta. Unfortunately, however, rural communities have smaller populations that, in turn, reflects smaller sample sizes. We did address this in the "Strengths and Limitations" section of the main paper (as our first strength and limitation), tying in the population sizes of the areas assessed, adding that we did audit a complete year of records thereby provide data that is reflective of practices audited.
We have clarified the P value with a footnote in Table 2 . For the mechanism of follow-up, however, the responses were not mutually exclusive (i.e., a patient could have follow up with both a family doctor and a specialist). Given this, computing a Chi-square test to capture a comparison as we have done for the mutually exclusive therapies is not appropriate. We have therefore performed comparisons for each category across the 3 sites and inserted the corresponding P values.
In the text of the results section (1 st paragraph), we are describing our population and have not performed statistical comparisons. For the 2 nd paragraph of the results section, we have used the Chi Square test (3x2) and inserted P values per the comments above.
We have clarified this in our methods where we describe classification of a proximal DVT -top of page 8.
Done.
Of the 25 patients, 5 had <7 days, 10 had 7-14 days and 10 had 15-20 days. This has been inserted into the manuscript.
We, a priori, set out to assess DOACs dosing given their newness on the market. We did not assess appropriateness of dosing of traditional therapies (LMWH or warfarin). While we agree that more details could have been provided for the DOACS (as done above) we do not believe comparing this to traditional therapies will bring value given the objectives of this manuscript.
We have not inserted a Chi square test here given that the type of follow up was not mutually exclusive (please refer to response above). We have left the statement to combine "specialist and VTE clinic" as patients seen in VTE clinics are seen by specialists.
Discussion
Integrated.
Please refer to prior comment, we believe we have both identified the small rural sample as a limitation, and also defended this in that these data are reflective of a full audit year based on the populations served.
Page 13 line 48 -again, the P-value should be given for the comparison. 
